Johnson & Johnson have announced they are paying $158 million to settle a lawsuit with the state of Texas that accused the company of improper marketing of the anti-psychotic drug Risperdal to state Medicaid recipients. The Texas settlement does not involve other state and federal Risperdal litigation.
Texas brought the lawsuit against J&J and several of its units alleging that company representatives “targeted every level of the Texas Medicaid Program with misrepresentations about the safety, superiority, efficacy, appropriate uses and cost effectiveness of Risperdal.”
Allen Jones, the whistleblower on the marketing practices of J&J told reporters that “Janssen ran amok…They trashed the Johnson & Johnson credo and they misused Texas and, I believe, well-meaning officials, to further their marketing aims,” Jones said. “They subverted science and they induced others to betray the people they were supposed to be taking care of. To me that is reprehensible,” Fox News reported.
The settlement will pay Texas and the federal government as well as the original plaintiff and his attorneys. This is the first settlement between any state and J&J over Risperdal.